ORGO

Organogenesis Holdings Inc.
CAPPED RATING

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis\'s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Organogenesis Holdings Inc. (ORGO) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.7
EV / EBITDA -4.7
Rev Growth YoY -69.9%
Gross Margin 67.0%
Price Return 3M -52.9%
Price Return 12M -87.5%
Catalyst Signal 0.00
Market Cap $105.2M
TTM Revenue $352.0M
Price / Sales 0.3
ROE -41.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C (2.4) B- (3.0) D- (1.0) C+ (2.6) C (2.4)
2026-11-07 B- (3.0) C+ (2.6) B (3.5) D- (1.0) C+ (2.7) C+ (2.6)
2026-10-31 B- (3.0) C+ (2.6) B (3.2) D- (0.8) C+ (2.7) C (2.5)
2026-10-24 B- (3.0) C+ (2.6) B (3.2) D- (0.9) C+ (2.6) C (2.5)
2026-10-17 B- (3.0) C+ (2.6) B (3.2) D- (0.8) C+ (2.6) C (2.5)
Page 1 of 8
…